D. Glebe, Recent advances in hepatitis B virus research: A German point of view, World Journal of Gastroenterology, vol.13, issue.1, pp.8-13, 2007.
DOI : 10.3748/wjg.v13.i1.8

A. Wasley, J. Miller, and L. Finelli, Centers for Disease Control and Prevention (CDC) Surveillance for acute viral hepatitis?United States, MMWR Surveill Summ, vol.56, pp.1-24, 2005.

Y. Liaw, J. Sung, and W. Chow, Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease, New England Journal of Medicine, vol.351, issue.15, pp.1521-1531, 2004.
DOI : 10.1056/NEJMoa033364

G. Arora and E. Keeffe, Chronic hepatitis B with advanced hepatic fibrosis or cirrhosis: impact of antiviral therapy, Rev Gastroenterol Disord, vol.7, pp.63-73, 2007.

F. Zoulim, In Vitro Models for Studying Hepatitis B Virus Drug Resistance, Seminars in Liver Disease, vol.26, issue.2, pp.171-180, 2006.
DOI : 10.1055/s-2006-939759

A. Bartholomeusz and S. Locarnini, Antiviral Drug Resistance: Clinical Consequences and Molecular Aspects, Seminars in Liver Disease, vol.26, issue.2, pp.162-170, 2006.
DOI : 10.1055/s-2006-939758

A. Lok, C. Lai, and N. Leung, Long-term safety of lamivudine treatment in patients with chronic hepatitis B, Gastroenterology, vol.125, issue.6, pp.1714-1722, 2003.
DOI : 10.1053/j.gastro.2003.09.033

P. Andreone, A. Gramenzi, and C. Cursaro, High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance, Journal of Viral Hepatitis, vol.31, issue.5, pp.439-442, 2004.
DOI : 10.1002/hep.510270243

S. Locarnini, Molecular Virology of Hepatitis B Virus, Seminars in Liver Disease, vol.24, issue.1, pp.3-10, 2004.
DOI : 10.1055/s-2004-828672

H. Norder, A. Courouce, and L. Magnius, Complete Genomes, Phylogenetic Relatedness, and Structural Proteins of Six Strains of the Hepatitis B Virus, Four of Which Represent Two New Genotypes, Virology, vol.198, issue.2, pp.489-503, 1994.
DOI : 10.1006/viro.1994.1060

J. Beck and M. Nassal, Hepatitis B virus replication, World Journal of Gastroenterology, vol.13, issue.1, pp.48-64, 2007.
DOI : 10.3748/wjg.v13.i1.48

H. Okamoto, M. Imai, and M. Kametani, Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission, Jpn J Exp Med, vol.57, pp.231-236, 1987.

A. Bartholomeusz and S. Locarnini, Hepatitis B virus mutations associated with antiviral therapy, Journal of Medical Virology, vol.38, issue.S1, pp.52-55, 2006.
DOI : 10.1002/jmv.20608

S. Locarnini, A. Hatzakis, and J. Heathcote, Management of antiviral resistance in patients with chronic hepatitis B, Antivir Ther, vol.9, pp.679-693, 2004.

D. Silva, L. Pinho, J. Sitnik, and R. , Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B, Journal of Gastroenterology, vol.36, issue.7, pp.476-485, 2001.
DOI : 10.1007/s005350170071

T. Wright, Clinical Trial Results and Treatment Resistance with Lamivudine in Hepatitis B, Seminars in Liver Disease, vol.24, issue.1, pp.31-36, 2004.
DOI : 10.1055/s-2004-828676

J. Dienstag, R. Goldin, and E. Heathcote, Histological outcome during long-term lamivudine therapy, Gastroenterology, vol.124, issue.1, pp.105-117, 2003.
DOI : 10.1053/gast.2003.50013

M. Yuen, T. Kato, and M. Mizokami, Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations, Journal of Hepatology, vol.39, issue.5, pp.850-855, 2003.
DOI : 10.1016/S0168-8278(03)00388-X

S. Ahmed, S. Tavan, D. Pichoud, and C. , Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B, Hepatology, vol.32, pp.1078-1088, 2000.

D. Mutimer, D. Pillay, and P. Shields, Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient, Gut, vol.46, issue.1, pp.107-113, 2000.
DOI : 10.1136/gut.46.1.107

F. Zoulim, Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection, Antiviral Research, vol.64, issue.1, pp.1-15, 2004.
DOI : 10.1016/S0166-3542(04)00162-7
URL : https://hal.archives-ouvertes.fr/inserm-00136413

M. Hussain and A. Lok, Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B, Journal of Viral Hepatitis, vol.6, issue.3, pp.183-194, 1999.
DOI : 10.1016/S0168-8278(97)80125-0

O. Poch, I. Sauvaget, and M. Delarue, Identification of four conserved motifs among the RNA-dependent polymerase encoding elements, EMBO J, vol.8, pp.3867-3874, 1989.

M. Allen, M. Deslauriers, and C. Andrews, Identification and characterization of mutations in hepatitis B virus resistant to lamivudine, Hepatology, vol.15, issue.6, pp.1670-1677, 1998.
DOI : 10.1002/hep.510270628

W. Delaney, H. Yang, and C. Westland, The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro, Journal of Virology, vol.77, issue.21, pp.11833-11841, 2003.
DOI : 10.1128/JVI.77.21.11833-11841.2003

L. Fu and Y. Cheng, Role of Additional Mutations outside the YMDD Motif of Hepatitis B Virus Polymerase in l(???)SddC (3TC) Resistance, Biochemical Pharmacology, vol.55, issue.10, pp.1567-1572, 1998.
DOI : 10.1016/S0006-2952(98)00050-1

B. Seigneres, P. Martin, and B. Werle, Effects of Pyrimidine and Purine Analog Combinations in the Duck Hepatitis B Virus Infection Model, Antimicrobial Agents and Chemotherapy, vol.47, issue.6, pp.1842-1852, 2003.
DOI : 10.1128/AAC.47.6.1842-1852.2003

M. Curtis, Y. Zhu, and K. Borroto-esoda, [56] HBV RTI233V POLYMERASE VARIANT REMAINS SENSITIVE TO ADEFOVIR, Journal of Hepatology, vol.46, pp.26-27, 2007.
DOI : 10.1016/S0168-8278(07)61654-7

S. Hadziyannis, N. Tassopoulos, and E. Heathcote, Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic, CHRONIC HEPATITIS B AND ANTIVIRAL RESISTANCE, p.273, 2008.

K. Borroto-esoda, S. Arterburn, and A. Snow, 483 Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg-negative patients, Journal of Hepatology, vol.44, issue.2, pp.179-180, 2006.
DOI : 10.1016/S0168-8278(06)80483-6

D. Langley, A. Walsh, and C. Baldick, Inhibition of Hepatitis B Virus Polymerase by Entecavir, Journal of Virology, vol.81, issue.8, pp.3992-4001, 2007.
DOI : 10.1128/JVI.02395-06

R. Colonno, R. Rose, and C. Baldick, Entecavir resistance is rare in nucleoside na??ve patients with hepatitis B, Hepatology, vol.37, issue.6, pp.1656-1665, 2006.
DOI : 10.1002/hep.21422

D. Tenney, R. Rose, and C. Baldick, Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present, Antimicrobial Agents and Chemotherapy, vol.51, issue.3, pp.902-911, 2007.
DOI : 10.1128/AAC.00833-06

R. Colonno, R. Rose, and K. Pokornowski, [781] FOUR YEAR ASSESSMENT OF ETV RESISTANCE IN NUCLEOSIDE-NAIVE AND LAMIVUDINE REFRACTORY PATIENTS, Journal of Hepatology, vol.46, issue.1, p.294, 2007.
DOI : 10.1016/S0168-8278(07)62379-4

M. Seifer, A. Patty, and D. Dukhan, Telbivudine (LdT) preferentially inhibits second () strand HBV DNA synthesis (abstr), Gastroenterology, vol.128, issue.2, pp.742-743, 2005.

C. Lai, E. Gane, and C. Hsu, Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine (abstr), Hepatology, vol.44, p.222, 2006.

S. Lim, T. Ng, and N. Kung, A Double-blind Placebo-Controlled Study of Emtricitabine in Chronic Hepatitis B, Archives of Internal Medicine, vol.166, issue.1, pp.49-56, 2006.
DOI : 10.1001/archinte.166.1.49

H. Yang, X. Qi, and A. Sabogal, Cross-resistance testing of nextgeneration nucleoside and nucleotide analogues against lamivudine-resistant HBV, Antivir Ther, vol.10, pp.625-633, 2005.

R. Gish, H. Trinh, and N. Leung, Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study, Journal of Hepatology, vol.43, issue.1, pp.60-66, 2005.
DOI : 10.1016/j.jhep.2005.02.017

W. Delaney, A. Ray, and H. Yang, Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus, Antimicrobial Agents and Chemotherapy, vol.50, issue.7, pp.2471-2477, 2006.
DOI : 10.1128/AAC.00138-06

O. Lada, Y. Benhamou, and A. Cahour, In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir, Antivir Ther, vol.9, pp.353-363, 2004.

F. Van-bömmel, B. Zollner, and C. Sarrazin, Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy, Hepatology, vol.126, issue.2, pp.318-325, 2006.
DOI : 10.1002/hep.21253

A. Van-der-eijk, B. Hansen, and H. Niesters, Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants, Journal of Viral Hepatitis, vol.37, issue.2, pp.364-372, 2005.
DOI : 10.1053/jhep.2001.28509

A. Lok and B. Mcmahon, Chronic hepatitis B, Hepatology, vol.4, issue.RR-16, pp.507-539, 2007.
DOI : 10.1002/hep.21513

E. Keeffe, D. Dieterich, and S. Han, A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update, Clinical Gastroenterology and Hepatology, vol.4, issue.8, pp.936-962, 2006.
DOI : 10.1016/j.cgh.2006.05.016

H. Tillmann, Antiviral therapy and resistance with hepatitis B virus infection, World Journal of Gastroenterology, vol.13, issue.1, pp.125-140, 2007.
DOI : 10.3748/wjg.v13.i1.125

A. Lok, F. Zoulim, and S. Locarnini, Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay, Journal of Clinical Microbiology, vol.40, issue.10, pp.3729-3734, 2002.
DOI : 10.1128/JCM.40.10.3729-3734.2002

F. Zoulim, New Nucleic Acid Diagnostic Tests in Viral Hepatitis, Seminars in Liver Disease, vol.26, issue.4, pp.309-317, 2006.
DOI : 10.1055/s-2006-951602

N. Tran, R. Berne, and R. Chann, European Multicenter Evaluation of High-Density DNA Probe Arrays for Detection of Hepatitis B Virus Resistance Mutations and Identification of Genotypes, Journal of Clinical Microbiology, vol.44, issue.8, pp.2792-2800, 2006.
DOI : 10.1128/JCM.00295-06

J. Tang and D. Pillay, Transmission of HIV-1 drug resistance, Journal of Clinical Virology, vol.30, issue.1, pp.1-10, 2004.
DOI : 10.1016/j.jcv.2003.12.002

M. Sherman, C. Yurdaydin, and J. Sollano, Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B, Gastroenterology, vol.130, issue.7, pp.2039-2049, 2006.
DOI : 10.1053/j.gastro.2006.04.007

M. Peters, H. Hann, and P. Martin, Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary???s Hospital, London, England); C. Trepo (Hopital H??tel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ)., Gastroenterology, vol.126, issue.1, pp.91-101, 2004.
DOI : 10.1053/j.gastro.2003.10.051

R. Perrillo, H. Hann, and D. Mutimer, Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus, Gastroenterology, vol.126, issue.1, pp.81-90, 2004.
DOI : 10.1053/j.gastro.2003.10.050

T. Chang, R. Gish, and S. Hadziyannis, A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients, Gastroenterology, vol.129, issue.4, pp.1198-1209, 2005.
DOI : 10.1053/j.gastro.2005.06.055

I. Rapti, E. Dimou, and P. Mitsoula, Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B, Hepatology, vol.50, issue.2, pp.307-313, 2007.
DOI : 10.1002/hep.21534

P. Lampertico, M. Vigano, and E. Manenti, Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine, Hepatology, vol.126, issue.6, pp.1414-1419, 2005.
DOI : 10.1002/hep.20939

A. Luber, Genetic barriers to resistance and impact on clinical response EJIAS: eJournal of the International Available at: http://www.medscape.com/ viewarticle, AIDS Society, vol.769, pp.1-11, 2005.

C. Lai, N. Leung, and E. Teo, A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen???Positive Chronic Hepatitis B, Gastroenterology, vol.129, issue.2, pp.528-536, 2005.
DOI : 10.1016/j.gastro.2005.05.053

J. Sung, J. Lai, and S. Zeuzem, A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipovoxil (ADV) for treatment na??ve patients with chronic hepatitis B (CHB): Week 52 analysis, Journal of Hepatology, vol.38, issue.2, pp.25-26, 2003.
DOI : 10.1016/S0168-8278(03)80485-3

G. Lau, H. Cooksley, and R. Ribeiro, Randomised, double-blind study comparing adefovir dipivoxil plus emtricitabine combination therapy versus adefovir alone in HBeAg() chronic hepatitis B: efficacy and mechanisms of treatment response (abstr), Hepatology, vol.40, p.272, 2004.

P. Marcellin, G. Lau, and F. Bonino, Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B, New England Journal of Medicine, vol.351, issue.12, pp.1206-1217, 2004.
DOI : 10.1056/NEJMoa040431

N. Nikolaidis, O. Giouleme, and K. Tziomalos, Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients, Journal of Gastroenterology and Hepatology, vol.102, issue.11, pp.1721-1725, 2005.
DOI : 10.1016/S0168-8278(02)00431-2

M. Yuen, D. Wong, and J. Fung, Predictive value of HBV DNA levels at frequent time points during early and maintenance phase of 5-year lamivudine and mutational profiles of reverse transcriptase (RT) and surface (S) genes (abstr), Hepatology, vol.44, p.557, 2006.